Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Other Gross PP&E Adjustments (2019 - 2025)

Vivos Therapeutics has reported Other Gross PP&E Adjustments over the past 7 years, most recently at $1.3 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 70.32% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 70.32% year-over-year, with the annual reading at $1.3 million for FY2025, 70.32% down from the prior year.
  • Other Gross PP&E Adjustments was $1.3 million for Q4 2025 at Vivos Therapeutics, down from $4.8 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $4.9 million in Q3 2024 and troughed at $1.3 million in Q4 2025.
  • The 5-year median for Other Gross PP&E Adjustments is $3.7 million (2021), against an average of $3.5 million.
  • Year-over-year, Other Gross PP&E Adjustments skyrocketed 139.38% in 2021 and then tumbled 70.32% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $2.5 million in 2021, then decreased by 7.18% to $2.4 million in 2022, then skyrocketed by 57.49% to $3.7 million in 2023, then increased by 18.37% to $4.4 million in 2024, then tumbled by 70.32% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Gross PP&E Adjustments are $1.3 million (Q4 2025), $4.8 million (Q3 2025), and $4.4 million (Q2 2025).